Observational Study of Effect of Radiation Therapy to Immuno Status in HIV-cancer Patients
NCT01546376 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2012-03-07
Summary
Objectives: To study immunostatus (CD4) and HIV viral load in HIV-cancer patients before RT and last weeks of RT .
Conditions
- To Study Immunostatus of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RT
- To Study HIV Viral Load of HIV-cancer Patients Who Recived RT Befor RT and Last Week of RT
Interventions
- RADIATION
-
Radiation therapy
External photon beam radiation therapy dosage 4000-7000 CGy
- OTHER
-
Venepuncture
Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
Sponsors & Collaborators
-
Department of Medical Services Ministry of Public Health of Thailand
lead OTHER_GOV
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-08-31
Countries
- Thailand
Study Locations
More Related Trials
-
Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand
NCT00433030 ·Status: COMPLETED
-
Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD
NCT04311944 ·Status: UNKNOWN ·Phase: NA
-
Raltegravir Intensification in HIV-infected Patients
NCT00631449 ·Status: COMPLETED ·Phase: PHASE4
-
Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery
NCT00562510 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan
NCT01467349 ·Status: COMPLETED
-
Pharmacokinetics of Low Dose Raltegravir
NCT01159132 ·Status: COMPLETED ·Phase: PHASE2
-
Same-Day Antiretroviral Therapy Initiation
NCT04032028 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
NCT01213316 ·Status: COMPLETED
-
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
NCT00781287 ·Status: TERMINATED ·Phase: PHASE4
-
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
NCT06044792 ·Status: NOT_YET_RECRUITING
-
Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
NCT01078246 ·Status: COMPLETED
-
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
NCT04644029 ·Status: TERMINATED ·Phase: PHASE3
-
Study to Determine Interaction Between the Use of Feminizing Hormone Therapy and Antiretroviral Agents Concomitantly Among Transgender Women
NCT03620734 ·Status: COMPLETED
-
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
NCT00476853 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Study of Raltegravir Lipodystrophy IISP
NCT01164605 ·Status: UNKNOWN ·Phase: NA
-
Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load
NCT00515827 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
NCT03563742 ·Status: TERMINATED ·Phase: PHASE3
-
Post Analytic Treatment Interruption Study
NCT02761200 ·Status: RECRUITING
-
Study of the Effectiveness of Passive Immunotherapy in HIV-Infected Patients Who Are in Virologic Failure
NCT00353327 ·Status: SUSPENDED ·Phase: PHASE2/PHASE3
-
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
NCT05584397 ·Status: ENROLLING_BY_INVITATION
-
Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen
NCT02191332 ·Status: COMPLETED
-
Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation
NCT02771054 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients.(RalAge)
NCT03579485 ·Status: UNKNOWN
-
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
NCT01019551 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
NCT03631732 ·Status: COMPLETED ·Phase: PHASE3